During the last session, Enanta Pharmaceuticals Inc (NASDAQ:ENTA)’s traded shares were 0.32 million, with the beta value of the company hitting 0.54. At the end of the trading day, the stock’s price was $5.53, reflecting an intraday loss of -0.18% or -$0.01. The 52-week high for the ENTA share is $17.80, that puts it down -221.88 from that peak though still a striking 14.83% gain since the share price plummeted to a 52-week low of $4.71. The company’s market capitalization is $117.21M, and the average intraday trading volume over the past 10 days was 0.66 million shares, and the average trade volume was 457.15K shares over the past three months.
Enanta Pharmaceuticals Inc (ENTA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.29. ENTA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.35.
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) trade information
Enanta Pharmaceuticals Inc (ENTA) registered a -0.18% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.18% in intraday trading to $5.53, hitting a weekly high. The stock’s 5-day price performance is 14.02%, and it has moved by -11.94% in 30 days. Based on these gigs, the overall price performance for the year is -54.63%. The short interest in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is 3.44 million shares and it means that shorts have 20.91 day(s) to cover.
The consensus price target of analysts on Wall Street is $56, which implies an increase of 90.12% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $54 and $87 respectively. As a result, ENTA is trading at a discount of -1473.24% off the target high and -876.49% off the low.
Enanta Pharmaceuticals Inc (ENTA) estimates and forecasts
Statistics show that Enanta Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Enanta Pharmaceuticals Inc (ENTA) shares have gone down -63.18% during the last six months, with a year-to-date growth rate less than the industry average at 10.04% against 16.80. In the rating firms’ projections, revenue will increase 4.56% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.25M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 15.94M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 18M and 17.05M respectively. In this case, analysts expect current quarter sales to shrink by -4.19% and then drop by -6.52% in the coming quarter.
While earnings are projected to return 11.12% in 2025, the next five years will return 14.06% per annum.
ENTA Dividends
Enanta Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Enanta Pharmaceuticals Inc (NASDAQ:ENTA)’s Major holders
Enanta Pharmaceuticals Inc insiders own 6.09% of total outstanding shares while institutional holders control 100.66%, with the float percentage being 107.19%. FARALLON CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 154.0 institutions own stock in it. As of 2024-06-30, the company held over 2.1 million shares (or 9.8914% of all shares), a total value of $27.17 million in shares.
The next largest institutional holding, with 1.93 million shares, is of VANGUARD GROUP INC’s that is approximately 9.1331% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $25.09 million.
Also, the Mutual Funds coming in first place with the largest holdings of Enanta Pharmaceuticals Inc (ENTA) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 629.6 shares. This amounts to just over 2.97 percent of the company’s overall shares, with a $3.48 million market value. The same data shows that the other fund manager holds slightly less at 524.38, or about 2.47% of the stock, which is worth about $2.9 million.
